The heart in human dystrophinopathies
- PMID: 12589117
- DOI: 10.1159/000068446
The heart in human dystrophinopathies
Abstract
Dystrophinopathies are due to mutations in the dystrophin gene on chromosome Xp21.1 and comprise the allelic entities Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) and X-linked dilative cardiomyopathy (XLDCM). In all three entities, the heart is affected to various degrees, depending on the stage of the disease and the type of the mutation (cardiac involvement, CI). The pathoanatomic evidence of CI in dystrophinopathies is the replacement of myocardium by connective tissue or fat. In DMD/BMD, the left ventricular posterobasal and lateral walls are most extensively affected, sparing the right ventricle and the atrium. Degree and dynamics of CI vary among the three entities. In DMD/BMD, CI usually remains subclinical in the early stages of the disease. Typical initial manifestations of CI in DMD/BMD are sinus tachycardia, tall R1 in V1, prominent Q in I, aVL, V6 or in II, III, and aVF, increased QT dispersion and possibly autonomic dysfunction. Initially, echocardiography is normal or shows regional wall motion abnormalities in areas of fibrosis. With spreading of fibrosis, left ventricular dysfunction and ventricular arrhythmias additionally occur. In the final stages of the disease, systolic function may lead to heart failure and sudden death. Subclinical or clinical CI is present in about 90% of the DMD/BMD patients but is the cause of death in only 20% of the DMD and 50% of the BMD patients. XLDCM is a rapidly progressive, almost exclusively myocardial disorder, starting in teenage males as heart failure due to dilative cardiomyopathy (CMP), leading to death from intractable heart failure within 1-2 years after diagnosis. Therapy of arrhythmias and CMP in all three disorders follows the established cardiological recommendations. Due to its protective effect, ACE inhibitors are recommended already at the early stages of the disease. Beta-blockers may be an additional option if indicated.
Copyright 2003 S. Karger AG, Basel
Similar articles
-
Cardiac Involvement in Duchenne Muscular Dystrophy and Related Dystrophinopathies.Methods Mol Biol. 2018;1687:31-42. doi: 10.1007/978-1-4939-7374-3_3. Methods Mol Biol. 2018. PMID: 29067654
-
Dystrophinopathies.2000 Sep 5 [updated 2022 Jan 20]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. 2000 Sep 5 [updated 2022 Jan 20]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. PMID: 20301298 Free Books & Documents. Review.
-
Are there real benefits to implanting cardiac devices in patients with end-stage dilated dystrophinopathic cardiomyopathy? Review of literature and personal results.Acta Myol. 2019 Mar 1;38(1):1-7. eCollection 2019 Mar. Acta Myol. 2019. PMID: 31309174 Free PMC article. Review.
-
Relation of Cardiac Dysfunction to Rhythm Abnormalities in Patients With Duchenne or Becker Muscular Dystrophies.Am J Cardiol. 2016 Apr 15;117(8):1349-54. doi: 10.1016/j.amjcard.2016.01.031. Epub 2016 Jan 28. Am J Cardiol. 2016. PMID: 26952271
-
Dystrophin-Deficient Cardiomyopathy.J Am Coll Cardiol. 2016 May 31;67(21):2533-46. doi: 10.1016/j.jacc.2016.02.081. J Am Coll Cardiol. 2016. PMID: 27230049 Review.
Cited by
-
Cardiomyopathy in Duchenne Muscular Dystrophy and the Potential for Mitochondrial Therapeutics to Improve Treatment Response.Cells. 2024 Jul 9;13(14):1168. doi: 10.3390/cells13141168. Cells. 2024. PMID: 39056750 Free PMC article. Review.
-
Saccharomyces pastorianus Residual Biomass Immobilized in a Polymer Matrix as a Biosorbent for Reactive Dye Removal: Investigations in a Dynamic System.Polymers (Basel). 2024 Feb 9;16(4):491. doi: 10.3390/polym16040491. Polymers (Basel). 2024. PMID: 38399869 Free PMC article.
-
Artificial Intelligence to derive aligned strain in cine CMR to detect patients with myocardial fibrosis: an open and scrutinizable approach.Res Sq [Preprint]. 2024 Jan 5:rs.3.rs-3785677. doi: 10.21203/rs.3.rs-3785677/v1. Res Sq. 2024. PMID: 38260274 Free PMC article. Preprint.
-
Efficacy of exon-skipping therapy for DMD cardiomyopathy with mutations in actin binding domain 1.Mol Ther Nucleic Acids. 2023 Oct 19;34:102060. doi: 10.1016/j.omtn.2023.102060. eCollection 2023 Dec 12. Mol Ther Nucleic Acids. 2023. PMID: 38028197 Free PMC article.
-
Electrocardiographic Changes in Jordanian Patients With Becker Muscular Dystrophy.Cureus. 2023 Oct 24;15(10):e47553. doi: 10.7759/cureus.47553. eCollection 2023 Oct. Cureus. 2023. PMID: 38022137 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous